Group 1 - The core point of the news is the performance and holdings of the China Europe Medical Health Mixed A Fund, which has shown a recent decline in net value but positive returns over various time frames [1] - As of August 12, 2025, the latest net value of the fund is 1.9165 yuan, reflecting a decrease of 0.56%. The fund's one-month return is 7.20%, six-month return is 23.93%, and year-to-date return is 22.17% [1] - The fund's top ten stock holdings account for a total of 54.73%, with notable positions in WuXi AppTec (10.39%), Hengrui Medicine (9.69%), and Kanglong Chemical (5.05%) among others [1] Group 2 - The China Europe Medical Health Mixed A Fund was established on September 29, 2016, and as of June 30, 2025, it has a total scale of 15.638 billion yuan [1] - The fund is managed by two key individuals: Ms. Ge Lan, who has been the fund manager since its inception, and Ms. Zhao Lei, who took over management on July 4, 2025 [2]

Core Viewpoint - Kanglong Chemical announced the approval of a capital increase and amendments to its articles of association during the shareholder meetings held on June 20, 2025 [1] Group 1 - The company completed the necessary business registration changes and obtained a new business license from the Beijing Economic and Technological Development Zone Market Supervision Administration [1]

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 海外監管公告 本公告乃康龍化成（北京）新藥技術股份有限公司（「本公司」）根據香港聯合交易所 有限公司證券上市規則第13.10B條作出。 茲載列本公司於深圳證券交易所網站刊登公告如下，僅供參閱。 承董事會命 康龍化成（北京）新藥技術股份有限公司 主席 樓柏良博士 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）于 2025 年 6 月 20 日召开的 2024 年年度股东大会、2025 年第一次 A 股类别股东大会及 2025 年第一次 H 股类别股东大会审议通 ...

近日，公司办理完成相关内容的工商变更登记手续，并取得了北京经济技术 开发区市场监督管理局换发的《营业执照》。公司新换发的《营业执照》基本信 息如下： 统一社会信用代码：9111030276350109XG 康龙化成（北京）新药技术股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）于 2025 年 6 月 20 日召开的 2024 年年度股东大会、2025 年第一次 A 股类别股东大会及 2025 年第一次 H 股类别股东大会审议通过了《关于增加注册资本、修订<公司章程> 的议案》。具体内容详见公司于 2025 年 3 月 27 日披露在巨潮资讯网 （www.cninfo.com.cn）的《关于注册资本增加、修订<公司章程>的公告》（公告 编号：2025-017）。 证券代码：300759 证券简称：康龙化成 公告编号：2025-040 名称：康龙化成（北京）新药技术股份有限公司 类型：股份有限公司（港澳台投资、上市） 法定代表人：楼柏良 注册资本：人民 ...

Summary of Key Points Core Viewpoint - The 2024 A-share Secretary Data Report indicates that the total salary of A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan, highlighting the significant role of secretaries in connecting investors and listed companies [1][2]. Group 1: Overall Salary and Demographics - The total salary for A-share listed company secretaries in 2024 is 4.086 billion yuan, with an average annual salary of 754,300 yuan [1]. - Among the secretaries, those aged 40 and below constitute 43% of the market, while those aged 50 and above account for 22% [1]. - The educational background of secretaries shows that 34% hold a bachelor's degree, 52% have a master's degree, and 14% possess a doctoral degree [1]. Group 2: Industry-Specific Salary Insights - The average annual salary for secretaries in the pharmaceutical and medical service sector is 839,200 yuan [2]. - The distribution of salaries shows that 24% earn below 500,000 yuan, 48% earn between 500,000 and 1 million yuan, and 28% earn above 1 million yuan [2]. - The top three highest-paid secretaries are Gilbert Shing Chung Li from Kanglong Chemical with 1.9855 million yuan, Gao Dapeng from Zhaoyan New Drug with 1.7384 million yuan, and Xu Xiangke from Kailaiying with 1.6114 million yuan [2].

Group 1 - The stock price of Kanglong Chemical is reported at 28.90 yuan, down 1.83% from the previous trading day, with a trading volume of 1.184 billion yuan [1] - The company operates in the medical services sector as a CRO (Contract Research Organization), providing drug research and development services across various fields including laboratory chemistry, biological sciences, and clinical research services [1] - On August 7, the company stated on an interactive platform that the impact of the US tariffs on its business is limited, as the export of commercial goods constitutes a small portion of its operations [1] Group 2 - On August 7, the net outflow of main funds was 159 million yuan, with a cumulative net outflow of 471 million yuan over the past five trading days [2]

Group 1 - The core viewpoint is that Kanglong Chemical's business has been minimally affected by the recent U.S. tariffs, as their primary focus is on providing R&D services, with a small proportion of their business related to commercial goods exports [2] - The company has not received any feedback from clients or partners indicating that tariff issues have impacted their business collaborations [2] - Kanglong Chemical is closely monitoring macroeconomic uncertainties and related policy developments, while also advising investors to be aware of investment risks in the context of geopolitical factors [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） 中華人民共和國，北京 2025年8月7日 （股份代號：3759） 於本公告日期，董事會包括執行董事樓柏良博士、樓小強先生及鄭北女士；非執 行董事李家慶先生及萬璇女士；獨立非執行董事李麗華女士、曾坤鴻先生及余堅 先生。 董事會會議通告 康龍化成（北京）新藥技術股份有限公司（「本公司」）董事會（「董事會」）謹此宣 佈，董事會會議將於2025年8月21日（星期四）舉行，藉以（其中包括）審議及批准 本公司及其附屬公司截至2025年6月30日止六個月之中期業績。 承董事會命 康龍化成（北京）新藥技術股份有限公司 主席 樓柏良博士 ...

格隆汇8月7日丨康龙化成(03759.HK)宣布，董事会会议将于2025年8月21日（星期四）举行，藉以（其 中包括）审议及批准公司及其附属公司截至2025年6月30日止六个月的中期业绩。 ...

格隆汇8月7日丨康龙化成(03759.HK)宣布，董事会会议将于2025年8月21日（星期四）举行，藉以（其 中包括）审议及批准公司及其附属公司截至2025年6月30日止六个月的中期业绩。 ...